...
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Tolerance to anxiolytic- and antidepressant-like effects of a partial agonist of glycineB receptors.
【24h】

Tolerance to anxiolytic- and antidepressant-like effects of a partial agonist of glycineB receptors.

机译:耐受甘氨酸B受体部分激动剂的抗焦虑和抗抑郁样作用。

获取原文
获取原文并翻译 | 示例

摘要

The present study examined effects of acute and repeated administration of 1-aminocyclopropanecarboxylic acid (ACPC), a partial agonist of glycineB receptors, in the conflict drinking test and the forced swim test in rats. Diazepam and imipramine were used, respectively, as reference drugs in those tests. In the conflict drinking test, acute administration of ACPC (200 mg/kg) increased fivefold the number of punished licks. A three- and fivefold increase in the number of punished licks was observed in rats treated repeatedly with ACPC (200 mg/kg daily; 14 days) and challenged with the same dose of the drug 24 h or 4 days later, respectively. A single injection of ACPC (400 mg/kg) reduced by 40% the immobility time in the forced swim test. In rats treated repeatedly with ACPC (400 mg/kg daily; 14 days) and challenged with the same dose 24 h or 4 days later, the drug either produced no significant effect or reduced the immobility time by 50%, respectively. On the other hand, no changes in anxiolytic- and antidepressant-like effects of chronically administered diazepam (10 mg/kg daily; 14 days) and imipramine (30 mg/kg daily; 14 days), respectively, were observed. The above results indicate that tolerance develops to the anxiolytic- and, particularly, to the antidepressant-like activity of ACPC.
机译:本研究检查了急性和反复施用1-氨基环丙烷羧酸(ACPC)(一种甘氨酸B受体的部分激动剂)在大鼠冲饮试验和强迫游泳试验中的作用。在那些试验中,地西p和丙咪嗪分别用作参考药物。在冲突饮酒测试中,ACPC(200 mg / kg)的急性给药使舔的次数增加了五倍。在反复用ACPC(每天200 mg / kg; 14天)治疗并分别在24 h或4天后用相同剂量的药物攻击的大鼠中,观察到的舔次数增加了三倍和五倍。在强制游泳测试中,单次注射ACPC(400 mg / kg)可将不动时间减少40%。在反复接受ACPC(每天400 mg / kg; 14天)并在24 h或4天后以相同剂量攻击的大鼠中,该药物未产生明显作用或使固定时间减少了50%。另一方面,长期服用地西epa(每天10 mg / kg; 14天)和丙咪嗪(每天30 mg / kg; 14天)的抗焦虑药和类抗抑郁药作用均未见变化。上述结果表明,对ACPC的抗焦虑活性,特别是对抗抑郁样活性的耐受性增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号